Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKTX Akari Therapeutics	$0.92 -0.4%	$1.08	$0.85 ▼ $4.00	$29.76M	0.22	37,447 shs	55,094 shs
CHRO Chromocell Therapeutics	$1.34 +6.3%	$6.68	$4.50 ▼ $38.00	$8.69M	3.63	47,337 shs	194,032 shs
FGEN FibroGen	$11.18 +0.8%	$7.29	$4.50 ▼ $21.94	$44.85M	0.76	68,852 shs	33,477 shs
SCYX SCYNEXIS	$0.82 +0.2%	$0.75	$0.66 ▼ $1.73	$34.14M	1.64	187,391 shs	118,474 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKTX Akari Therapeutics	-0.38%	-8.75%	-18.81%	-27.73%	-74.33%
CHRO Chromocell Therapeutics	0.00%	0.00%	0.00%	-86.19%	-84.33%
FGEN FibroGen	+0.81%	+17.81%	+48.08%	+35.52%	+11.49%
SCYX SCYNEXIS	+0.21%	-2.85%	+11.17%	+5.15%	-54.16%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKTX Akari Therapeutics	2.3551 of 5 stars	3.5	3.0	0.0	0.0	0.6	3.3	0.0
CHRO Chromocell Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FGEN FibroGen	4.642 of 5 stars	3.3	5.0	0.0	4.7	2.2	3.3	0.6
SCYX SCYNEXIS	0.996 of 5 stars	0.0	5.0	0.0	0.0	1.3	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKTX Akari Therapeutics	3.00	Buy	$5.00	442.59% Upside
CHRO Chromocell Therapeutics	0.00	N/A	N/A	N/A
FGEN FibroGen	2.50	Moderate Buy	$43.00	284.62% Upside
SCYX SCYNEXIS	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest CHRO, SCYX, FGEN, and AKTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/7/2025	FGEN FibroGen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$43.00
7/18/2025	AKTX Akari Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$5.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	$0.80 per share	N/A
CHRO Chromocell Therapeutics	N/A	N/A	N/A	N/A	($1.65) per share	N/A
FGEN FibroGen	$29.62M	1.52	N/A	N/A	($50.08) per share	-0.22
SCYX SCYNEXIS	$3.75M	9.12	N/A	N/A	$1.06 per share	0.77

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKTX Akari Therapeutics	-$19.79M	N/A	0.00	∞	N/A	N/A	-78.03%	-31.62%	9/25/2025 (Estimated)
CHRO Chromocell Therapeutics	-$7.38M	-$1.24	N/A	∞	N/A	N/A	N/A	-453.90%	N/A
FGEN FibroGen	-$47.58M	-$0.38	N/A	N/A	N/A	-3.86%	N/A	-27.34%	11/11/2025 (Estimated)
SCYX SCYNEXIS	-$21.29M	-$0.40	N/A	16.32	N/A	-599.05%	-43.04%	-28.21%	11/5/2025 (Estimated)

Latest CHRO, SCYX, FGEN, and AKTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	Q2 2025	SCYX SCYNEXIS	-$0.23	-$0.14	+$0.09	-$0.14	$0.15 million	$1.36 million
8/11/2025	Q2 2025	FGEN FibroGen	-$2.25	-$3.38	-$1.13	-$1.88	$2.88 million	$1.30 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	N/A
CHRO Chromocell Therapeutics	N/A	N/A	N/A	N/A	N/A
FGEN FibroGen	N/A	N/A	N/A	N/A	N/A
SCYX SCYNEXIS	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKTX Akari Therapeutics	N/A	0.19	0.19
CHRO Chromocell Therapeutics	N/A	0.60	0.60
FGEN FibroGen	N/A	1.04	1.02
SCYX SCYNEXIS	N/A	5.20	5.20

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKTX Akari Therapeutics	5.06%
CHRO Chromocell Therapeutics	77.96%
FGEN FibroGen	72.71%
SCYX SCYNEXIS	54.37%

Insider Ownership

Company	Insider Ownership
AKTX Akari Therapeutics	38.10%
CHRO Chromocell Therapeutics	16.40%
FGEN FibroGen	3.07%
SCYX SCYNEXIS	4.86%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKTX Akari Therapeutics	9	32.18 million	19.92 million	Not Optionable
CHRO Chromocell Therapeutics	4	6.49 million	5.04 million	N/A
FGEN FibroGen	570	4.04 million	3.92 million	Optionable
SCYX SCYNEXIS	60	41.92 million	39.89 million	Optionable

CHRO, SCYX, FGEN, and AKTX Headlines

Recent News About These Companies

Analysts Offer Predictions for SCYNEXIS FY2029 Earnings

August 21 at 2:56 AM | americanbankingnews.com

Scynexis reports Q2 EPS (14c), consensus (19c)

August 14, 2025 | msn.com

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 14, 2025 | finanznachrichten.de

SCYNEXIS Reports Improved Financials Amidst Strategic Developments

August 14, 2025 | msn.com

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 13, 2025 | globenewswire.com

SCYNEXIS (SCYX) to Release Quarterly Earnings on Thursday

August 13, 2025 | americanbankingnews.com

SCYNEXIS Inc. Advances Phase 3 Study for Invasive Candidiasis Treatment

August 8, 2025 | msn.com

SCYNEXIS Resumes Dosing in Phase 3 MARIO Study Following FDA Hold, Triggering $10M Milestone Payment Dispute with GSK

May 30, 2025 | nasdaq.com

SCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA Hold

May 28, 2025 | insidermonkey.com

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

May 28, 2025 | globenewswire.com

SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 15, 2025 | finance.yahoo.com

Scynexis to present preclinical data on SCY-247 at ESCMID Meeting

April 9, 2025 | markets.businessinsider.com

SCYNEXIS Full Year 2024 Earnings: Misses Expectations

March 14, 2025 | finance.yahoo.com

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

March 12, 2025 | markets.businessinsider.com

SCYNEXIS, Inc. Advances Phase 1 Trial of SCY-247 Antifungal and Prepares for Phase 3 MARIO Study Restart

March 12, 2025 | quiverquant.comQ

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

March 12, 2025 | globenewswire.com

SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections

December 18, 2024 | markets.businessinsider.com

Maxim Group Keeps Their Buy Rating on SCYNEXIS (SCYX)

December 5, 2024 | markets.businessinsider.com

SCYNEXIS’s Strong Financial Position and Strategic Advancements Drive Buy Rating

November 9, 2024 | markets.businessinsider.com

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

November 6, 2024 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHRO, SCYX, FGEN, and AKTX Company Descriptions

Akari Therapeutics NASDAQ:AKTX

$0.92 0.00 (-0.38%)

Closing price 08/22/2025 03:50 PM Eastern

Extended Trading

$0.93 +0.01 (+0.71%)

As of 08/22/2025 05:34 PM Eastern

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

Chromocell Therapeutics NYSE:CHRO

Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.

FibroGen NASDAQ:FGEN

$11.18 +0.09 (+0.81%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$11.14 -0.04 (-0.40%)

As of 08/22/2025 07:57 PM Eastern

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

SCYNEXIS NASDAQ:SCYX

$0.82 +0.00 (+0.21%)

Closing price 08/22/2025 03:58 PM Eastern

Extended Trading

$0.81 0.00 (-0.37%)

As of 08/22/2025 07:33 PM Eastern

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time